Our people: Nicolas
Our people: Nicolas
Director – Nicolas plays a major role developing the Life Sciences Strategy team in Switzerland, where he leads commercial strategy engagements.
Nicolas works in Life Sciences Strategy leading commercial strategy engagements for KPMG.
In the past years, you have built up your own team in the area of Life Sciences Strategy. What does your work consist of?
Our consulting activities focus on Life Sciences firms: Our client portfolio is made up of big pharmaceutical companies, biotechs and medtechs. Our value proposition concentrates on three areas. In Portfolio Strategy we evaluate the strategy of our clients to discern gaps in their product portfolio. This helps us to decide whether to invest or dispose. Licensing & Partnering offers assistance in in- and out-licensing of pharmaceutical assets as well as any partnership structure decisions. In the area of Commercial Strategy we help our clients to successfully launch their product or expand into new markets.
You have been working in the Life Sciences industry for the past decade. In your view, what makes it so fascinating?
The life science industry creates benefits for the health and well-being of our society. Thanks to new medicines and medical innovations, the healthcare system is continuously improving. Our job gives us the opportunity to make a significant contribution to that. The global relevance and international character of the industry make our work all the more dynamic and exciting.
“The life sciences industry creates benefits for the health and well-being of our society. Thanks to new medicines and medical innovations, the healthcare system improves continuously. Our job gives us the opportunity to make a significant contribution to that.”
Innovation is one of the big buzz words of our time. What role does innovation play in life science consulting?
Innovation is a significant distinguishing feature. Our clients expect us to come up with innovative solutions to their problems. A good example is our product launch tool. One of the problems of pharmaceutical companies is the immense complexity of their projects. Bringing a drug to the market is a formidable cross-functional project, with no less than 800 individual tasks that need to be carefully prioritized, sequenced and assigned.